Ingenuity Strengthens Management Team with Dr. Rudolph Potenzone


Mountain View, California, March 18, 2004 – Ingenuity announced today that Dr. Rudolph Potenzone has joined Ingenuity as Senior Vice President of Business Development & Strategic Planning. Dr. Rudolph Potenzone is a co-founder of ChemTelligence Partners and prior to joining Ingenuity was the CEO of LION bioscience Inc. With more than 25 years of cheminformatics experience, Potenzone previously worked at MDL as Senior Vice President for Marketing & Development where he managed the design, development and marketing of the company’s software and database products. Earlier, Dr. Potenzone was Director of Research and New Product Development at Chemical Abstracts Service (CAS), and, prior to CAS, at Polygen/Molecular Simulations, Inc. Dr. Potenzone brings over ten years of industrial experience managing chemical information systems. He holds a Ph.D. in macromolecular science from Case Western Reserve University in Cleveland Ohio and a bachelor of science degree in biophysics and microbiology from the University of Pittsburgh.

Jake Leschly, President and CEO of Ingenuity stated, “As a result of our early success with IPA, we now have an opportunity to build a powerful eco-system of partnerships. Identifying and forming these partnerships requires vision, planning, discipline, and execution. Rudy’s experience, expertise, and track record assure me he has what it takes to make this happen.”

“I am very excited to have the opportunity to work with Jake and his talented team,” Dr. Potenzone said. “The company has delivered IPA, one of the most exciting applications available today. The product is already helping many scientists understand the biological significance of their genomics and proteomics data.”

IPA Winter ’04 release is available for a free trial to qualified research scientists at, or by contacting Customer Care at 650.623.0818.

About Ingenuity Systems

Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View,